high response rate when using a bispecific antibody to treat R/R multiple myeloma.

Published Date: 12 Apr 2024

71 percent ORR that increased over time, along with a good safety record when using linvoseltamab.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Prostate cancer death risk is higher in late teens and early 20s weight gain.

2.

Bayer is transforming pharmaceutical research into women's health

3.

Biomarker panel offers hope for early pancreatic cancer detection

4.

A small rise in cancer was observed following the 1986 Chernobyl accident.

5.

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot